IL89793A - Medicinal product for the treatment of infection with retrovirus and a method for its preparation - Google Patents
Medicinal product for the treatment of infection with retrovirus and a method for its preparationInfo
- Publication number
- IL89793A IL89793A IL8979389A IL8979389A IL89793A IL 89793 A IL89793 A IL 89793A IL 8979389 A IL8979389 A IL 8979389A IL 8979389 A IL8979389 A IL 8979389A IL 89793 A IL89793 A IL 89793A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- component
- niruri
- combination
- administration
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 25
- 238000000034 method Methods 0.000 title claims description 23
- 208000005074 Retroviridae Infections Diseases 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title description 2
- 244000038594 Phyllanthus urinaria Species 0.000 claims description 45
- 102100034343 Integrase Human genes 0.000 claims description 26
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 26
- 230000002401 inhibitory effect Effects 0.000 claims description 17
- 241000700605 Viruses Species 0.000 claims description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 241001430294 unidentified retrovirus Species 0.000 claims description 9
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 8
- 241001130943 Phyllanthus <Aves> Species 0.000 claims description 6
- 238000007912 intraperitoneal administration Methods 0.000 claims description 5
- 241000714474 Rous sarcoma virus Species 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000003808 methanol extraction Methods 0.000 claims description 3
- 230000004083 survival effect Effects 0.000 claims description 2
- 230000000153 supplemental effect Effects 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 238000003809 water extraction Methods 0.000 claims 1
- 239000000284 extract Substances 0.000 description 26
- 230000005764 inhibitory process Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 12
- 239000006286 aqueous extract Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000825 pharmaceutical preparation Substances 0.000 description 10
- 238000003556 assay Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 239000012531 culture fluid Substances 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 241000725618 Duck hepatitis B virus Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000000798 anti-retroviral effect Effects 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 239000002035 hexane extract Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 244000173207 Phyllanthus amarus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229960002555 zidovudine Drugs 0.000 description 3
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002012 ayurvedic medicine Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229960005102 foscarnet Drugs 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WLNBMPZUVDTASE-HXIISURNSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO WLNBMPZUVDTASE-HXIISURNSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical group [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical group Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001379470 Phyllanthus fraternus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241001492404 Woodchuck hepatitis virus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011670 long-evans rat Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- YFNGWGVTFYSJHE-UHFFFAOYSA-K trisodium;phosphonoformate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O YFNGWGVTFYSJHE-UHFFFAOYSA-K 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/174,695 US4937074A (en) | 1988-03-29 | 1988-03-29 | Method of treating retrovirus infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL89793A0 IL89793A0 (en) | 1989-09-28 |
| IL89793A true IL89793A (en) | 1994-02-27 |
Family
ID=22637149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL8979389A IL89793A (en) | 1988-03-29 | 1989-03-29 | Medicinal product for the treatment of infection with retrovirus and a method for its preparation |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US4937074A (da) |
| EP (1) | EP0407452B1 (da) |
| JP (1) | JPH03505325A (da) |
| CN (1) | CN1037903A (da) |
| AU (1) | AU617068B2 (da) |
| DE (1) | DE68908701D1 (da) |
| DK (1) | DK234590D0 (da) |
| IL (1) | IL89793A (da) |
| WO (1) | WO1989009059A1 (da) |
| ZA (1) | ZA892308B (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02270824A (ja) * | 1989-04-13 | 1990-11-05 | Snow Brand Milk Prod Co Ltd | 逆転写酵素阻害剤 |
| US5178865A (en) * | 1990-06-19 | 1993-01-12 | Cedars-Sinai Medical Center | Chinese herbal extracts in the treatment of hiv related disease in vitro |
| AU644669B2 (en) * | 1990-06-19 | 1993-12-16 | Cedars-Sinai Medical Center | Chinese herbal extracts in the treatment of hiv related disease |
| US5141923A (en) * | 1990-12-31 | 1992-08-25 | Immunology, Inc., A California Corporation | Methods for the treatment of retroviral infections |
| US5360714A (en) * | 1992-08-28 | 1994-11-01 | Fox Chase Cancer Center | Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activities and methods of measuring the activities thereof |
| US5334525A (en) * | 1992-08-28 | 1994-08-02 | Fox Chase Cancer Center | Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activities and methods of measuring the activities thereof |
| WO1996010649A1 (en) * | 1994-09-30 | 1996-04-11 | Southwest Foundation For Biomedical Research | Isolated human hepatitis b virus polymerase and uses thereof |
| BR9913333A (pt) | 1998-08-25 | 2001-05-15 | Univ Yale | Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos |
| DE19919585A1 (de) | 1999-04-29 | 2000-12-07 | Cmi Ag | Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen |
| DE10030139A1 (de) * | 2000-06-20 | 2002-01-10 | Cmi Ag | Verwendung von Phyllanthusbesandteilen zur Behandlung oder Prophylaxe von Infekten durch Flaviviridae |
| EP1333848B1 (en) * | 2000-10-06 | 2006-04-05 | Phytrix AG | Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a retrovirus |
| ATE275413T1 (de) * | 2000-10-06 | 2004-09-15 | Phytrix Ag | Verfahren zur herstellung von phyllanthusextrakten |
| DE10120627A1 (de) * | 2001-04-26 | 2002-10-31 | Cmi Ag | Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren |
| US20050129780A1 (en) * | 2002-05-29 | 2005-06-16 | Holcomb-Halstead Terri L. | Relief of aids symptoms |
| EP2116253A1 (en) | 2008-05-07 | 2009-11-11 | Phytrix JV, LLC | Novel phyllanthus extract |
| CN103435704A (zh) * | 2013-08-26 | 2013-12-11 | 孟祥帅 | 一种豌豆淀粉的生产方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4673575A (en) * | 1985-04-26 | 1987-06-16 | Fox Chase Cancer Center | Composition, pharmaceutical preparation and method for treating viral hepatitus |
-
1988
- 1988-03-29 US US07/174,695 patent/US4937074A/en not_active Expired - Lifetime
-
1989
- 1989-03-28 AU AU34133/89A patent/AU617068B2/en not_active Ceased
- 1989-03-28 EP EP89904470A patent/EP0407452B1/en not_active Expired - Lifetime
- 1989-03-28 DE DE89904470T patent/DE68908701D1/de not_active Expired - Lifetime
- 1989-03-28 WO PCT/US1989/001270 patent/WO1989009059A1/en not_active Ceased
- 1989-03-28 JP JP1504343A patent/JPH03505325A/ja active Pending
- 1989-03-29 IL IL8979389A patent/IL89793A/en not_active IP Right Cessation
- 1989-03-29 CN CN89101876A patent/CN1037903A/zh active Pending
- 1989-03-29 ZA ZA892308A patent/ZA892308B/xx unknown
-
1990
- 1990-09-28 DK DK234590A patent/DK234590D0/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE68908701D1 (de) | 1993-09-30 |
| DK234590A (da) | 1990-09-28 |
| WO1989009059A1 (en) | 1989-10-05 |
| JPH03505325A (ja) | 1991-11-21 |
| EP0407452A1 (en) | 1991-01-16 |
| DK234590D0 (da) | 1990-09-28 |
| CN1037903A (zh) | 1989-12-13 |
| EP0407452A4 (en) | 1991-08-21 |
| EP0407452B1 (en) | 1993-08-25 |
| US4937074A (en) | 1990-06-26 |
| IL89793A0 (en) | 1989-09-28 |
| ZA892308B (en) | 1990-02-28 |
| AU3413389A (en) | 1989-10-16 |
| AU617068B2 (en) | 1991-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4937074A (en) | Method of treating retrovirus infection | |
| Lin et al. | Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol | |
| Sarin et al. | Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone | |
| US5521161A (en) | Method of treating HIV in humans by administration of ddI and hydroxycarbamide | |
| US5047435A (en) | Antiviral compositions containing aromatic polycyclic diones and method for treating retrovirus infections | |
| US6030980A (en) | Agent for the treatment of infections | |
| DE69032613T2 (de) | Zusammensetzung und verfahren zur behandlung viraler infektionen | |
| EP0199429A2 (en) | Manufacture of a medicament for treating viral hepatitis | |
| DE3881864T2 (de) | Antivirale zusammensetzungen mit aromatischen polycyclischen dionen sowie methode zur behandlung retroviraler infektionen. | |
| KR19990015612A (ko) | 황백피와 마타리 식물의 혼합추출물을 함유하는 c형 간염 치료제조성물 | |
| KR100239878B1 (ko) | 간질환 예방 및 치료용 생약조성물 | |
| KR101213599B1 (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 간기능 치료제 조성물 | |
| JPH09241157A (ja) | リソスペルメートｂ含有肝臓保護作用医薬組成物 | |
| AU760967B2 (en) | Herbal composition for the prophylaxis and treatment of AIDS | |
| JP4121957B2 (ja) | 藍調製物、ならびにそのヒト免疫不全ウイルスの感染予防または治療における用途 | |
| Wang et al. | Recent studies on Tripterygium wilfordii | |
| JPH11209282A (ja) | ベルゲニン及びその誘導体を有効成分とする肝機能改善剤 | |
| AU3423989A (en) | Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections | |
| JP2857388B1 (ja) | アカメガシワ樹皮のエキスを有効成分とする肝機能改善剤、肝機能改善飲料、及び肝機能改善茶 | |
| AU631989B2 (en) | Novel application of 4-carbamoyl-1-beta-d-ribofuranosyl imidazolium-5-olate | |
| KR100193216B1 (ko) | 황백피와 마타리 식물의 혼합 수추출물을 함유하는 후천성면역결핍증 치료제 조성물 | |
| KR20030064327A (ko) | 간염 치료제 및 예방제 또는 간보호제로 유용한 섬오갈피추출물 | |
| JPH07126180A (ja) | 発癌抑制剤 | |
| WO1989009055A1 (en) | Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections | |
| CN120960294A (zh) | 红茴香或其提取物在制备抗猪流行性腹泻病毒药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH | Patent void |